Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 986 phase I ascending-dose study in healthy subjects and heart failure patients
NL-OMON46755Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF) comparing AMG 986 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events and Clinically significant safety changes. Started Nov 2018; status: active, not recruiting.
02
Drugs
azelaprag
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON46755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46755.